Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

Autor: D. Dodick, K. Bruining, Catherine M. Dalton, W. Morrison, D. Derrington, A. Bowling, J. Adams, J. Hebert, S. Curtis, Minhua Yang, Gareth J. Barker, R. E. Kramer, J. P. Kelly, D. G. MacManus, Shôn Lewis, L. Costley, K. Bracht, E. Drexler, M. Malikowski, R. S. Murray, Clive Hawkins, K. Markopoulou, David P. Richman, William A. Sheremata, K. Nelson, M. Yeung, R. Wolintz, I. Rozentsvit, Joel Oger, Luanne M. Metz, Kathleen Healey, Jonathan L. Carter, Zahid Latif, J. Trotter, C. Mathews, C. Wallace, Jinan Al-Omaishi, Katherine Riester, Todd L. Richards, C. Webb, B. Harwick, Thomas E. Conturo, C. Gibson, E. Prenger, G. Foster, J. Forsyth, Michael Kaufman, L D Blumhardt, D. A H Cross, J. Curlis, James D. Bowen, C. Coombs, V. Orpe, Mark A. Agius, Omar Khan, C. Martinez, J. Takata, C. Graves, S. Putman, J. Scott, A. Diedrich, L. Capolino, J. Leitch, Per Soelberg Sørensen, M. Cochran, M. Buonocore, P. English, Christopher F. O'Brien, M. J. Keilson, A. Schneider, A. Miller, George Rice, Alexandros Tselis, C. Middleditch, S. Dombrowski, L. Wang, H. Oltazewska, J. Lauber, J. Heuser, H. Lew, Virginia Devonshire, M. Zvartau-Hinds, M. Burke, D. Patry, Paul O'Connor, M. Chang, Katherine A. Miszkiel, Lauren Seeberger, David W. Bates, L. Sciarra, E. Riddle, Robert P. Lisak, Michael Panzara, David Miller, R. Follmer, T. Jaspen, M. Din, T. Pepple, Christina Caon

Publikováno v: Multiple Sclerosis Journal. 11:568-572

Background: Natalizumab, a humanized monoclonal IgG4 antibody, is an a4-integrin antagonist, which inhibits the migration of inflammatory cells into the central nervous system, a key pathogenic mechanism in multiple sclerosis (MS). In a six month, ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38665639a011a220df8600c7e84283b2
https://doi.org/10.1191/1352458505ms1205oa

De novo mutation in theNotch3 gene causing CADASIL

Autor: David D. Dodick, Michaelle Cecillon, Elisabeth Tournier-Lasserve, M.G. Bousser, Anne Joutel, Joseph E. Parisi

Publikováno v: Annals of Neurology. 47:388-391

CADASIL, an autosomal dominant arteriopathy responsible for stroke and dementia, is caused by strongly stereotyped mutations in the Notch3 gene. We report a patient with a condition strongly suggestive of CADASIL (migraine, stroke, and white matter a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7fe9d5b30d543f8a86dc3e792cfef5ec
https://doi.org/10.1002/1531-8249(200003)47:3<388::aid-ana19>3.0.co

De novo mutation in the Notch3 gene causing CADASIL

Autor: A, Joutel, D D, Dodick, J E, Parisi, M, Cecillon, E, Tournier-Lasserve, M G, Bousser

Publikováno v: Annals of neurology. 47(3)

CADASIL, an autosomal dominant arteriopathy responsible for stroke and dementia, is caused by strongly stereotyped mutations in the Notch3 gene. We report a patient with a condition strongly suggestive of CADASIL (migraine, stroke, and white matter a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::87d4a40c6e5389500326b60459e79485
https://pubmed.ncbi.nlm.nih.gov/10716263

A 3 item screening instrument had moderate sensitivity and specificity for detecting migraine headaches

Autor: Alexander W. Chessman, D. Dodick, Richard B. Lipton, R. Sadovsky

Publikováno v: Evidence-Based Medicine. 9:56-56

Lipton RB, Dodick D, Sadovsky R, et al . A self-administered screener for migraine in primary care: The ID Migraine(TM) validation study. Neurology 2003;61:375–82. [OpenUrl][1][Abstract/FREE Full Text][2] Q In an outpatient primary care setting, wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89f494ffb9250cb4c4ef459369e77df6
https://doi.org/10.1136/ebm.9.2.56